In their work, there was an inverse relationship between LIF upregulation and CXCL9 expression in human GBM samples, and inhibition of LIF through RNAi or monoclonal antibody therapy could induce upregulation in CXCL9 resulting in improved T cell recruitment. This evidence concerns the gene CXCL9 and glioblastoma.